Compare Eli Lilly And Co (LLY) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Under Armour Inc Class A — how do they compare? Eli Lilly And Co trades at $1,141 (market cap $1.02T), while Under Armour Inc Class A trades at $7.29 (market cap $3.07B). The key difference: Eli Lilly And Co is far larger — about 332.2× Under Armour Inc Class A's market cap, and Eli Lilly And Co pays a 0.6% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| LLY | UAA | |
|---|---|---|
Market Cap | $1.02T | $3.07B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.24K | $8.14 |
52-Week Low | $625.65 | $4.17 |
Enterprise Value | $1.06T | $4.70B |
Dividend Yield | 0.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
Under Armour (UAA) trades at $7.28, down 2.02% amid mixed signals. The stock shows technical bullish momentum with strong moving average support, but faces fundamental challenges including a net loss of $201.27 million in 2025 and negative profit margins. Recent earnings showed Q4 2025 beat expectations but Q1 2026 missed, while the company maintains international growth momentum despite North American weakness.
The outlook remains cautious with analyst consensus price target of $5.96 below current levels. Investment opportunity exists in international expansion and DTC growth, but risks include persistent North American weakness, margin pressure, and negative cash flow trends that could pressure shareholder value in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
